Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 8/20 | 0.48 |
| ▸ | BCHE | P06276 | 5/20 | 0.48 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.47 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039110 | 0.91 | SIGMAR1 (0.51) | ALDH1A1ACHEBCHESIGMAR1HSD17B2 | |
| SCHEMBL1037264 | 0.89 | SLC2A1 (0.47) | SLC2A1ALDH1A1ACHEBCHESIGMAR1 | |
| SCHEMBL1033735 | 0.87 | KDM4E (0.44) | SLC2A1ALDH1A1ACHEBCHE | |
| SCHEMBL1036749 | 0.87 | KDM4E (0.48) | ALDH1A1ACHEBCHE | |
| SCHEMBL1037167 | 0.87 | SLC2A1 (0.55) | SLC2A1ACHESLC2A4SLC2A8 | |
| SCHEMBL1032923 | 0.87 | ACHE (0.43) | ALDH1A1ACHEBCHE | |
| SCHEMBL1034160 | 0.86 | SLC2A1 (0.47) | SLC2A1ACHEBCHESLC2A4SLC2A8 | |
| SCHEMBL1037998 | 0.86 | ACHE (0.42) | ACHEBCHE | |
| SCHEMBL1035600 | 0.86 | SMN1; SMN2 (0.45) | ALDH1A1ACHEBCHE | |
| SCHEMBL1038530 | 0.84 | ACHE (0.47) | ALDH1A1ACHEBCHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831173-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | disclosed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | SLC2A1 376/4885ALDH1A1 2450/4885ACHE 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.